Search research articles
Contact Us
Filters
Showing results (881-890 of 1,482) with videos related to
Page
of 149
Sort By:
Haematologica
|
November 4, 2021
AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill <i>FLT3</i>-ITD acute myeloid leukemia
Sean M Post, Huaxian Ma, Prerna Malaney, et al.
The Journal of Molecular Diagnostics : JMD
|
December 23, 2018
Ultra-Rapid Reporting of GENomic Targets (URGENTseq): Clinical Next-Generation Sequencing Results within 48 Hours of Sample Collection
Keyur P Patel, Roberto Ruiz-Cordero, Wei Chen, et al.
American Journal of Hematology
|
September 19, 2022
Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes
Daniel Rivera, Kunhwa Kim, Rashmi Kanagal-Shamanna, et al.
JCO Precision Oncology
|
May 17, 2023
Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in <i>ABL</i> Class Rearrangements
Jayastu Senapati, Elias Jabbour, Marina Konopleva, et al.
Blood Advances
|
December 19, 2023
Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax
Alex Bataller, Alexandre Bazinet, Courtney D DiNardo, et al.
American Journal of Hematology
|
February 16, 2024
Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups
Alex Bataller, Courtney D DiNardo, Alexandre Bazinet, et al.
Frontiers in Antibiotics
|
June 6, 2025
Inclusion of patient-centered, non-microbiological endpoints and biomarkers in tuberculosis drug trials
Andrew R DiNardo, Wilbert Sabiiti, Stephen H Gillespie, et al.
American Journal of Hematology
|
December 24, 2024
Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High-Risk Subtype That Warrants an Independent Prognostic Designation
Jayastu Senapati, Hagop M Kantarjian, Fadi G Haddad, et al.
The Journal of Sexual Medicine
|
November 1, 2019
Clinical and Genetic Predictors of Priapism in Sickle Cell Disease: Results from the Recipient Epidemiology and Donor Evaluation Study III Brazil Cohort Study
Mina Cintho Ozahata, Grier P Page, Yuelong Guo, et al.
The Lancet. Oncology
|
October 21, 2021
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial
Courtney D DiNardo, Andre C Schuh, Eytan M Stein, et al.
Page
of 149
Search research articles
Search
Showing results (881-890 of 1,482) with videos related to
Sort By:
Page
of 149
Haematologica
|
November 4, 2021
AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill <i>FLT3</i>-ITD acute myeloid leukemia
Sean M Post, Huaxian Ma, Prerna Malaney, et al.
The Journal of Molecular Diagnostics : JMD
|
December 23, 2018
Ultra-Rapid Reporting of GENomic Targets (URGENTseq): Clinical Next-Generation Sequencing Results within 48 Hours of Sample Collection
Keyur P Patel, Roberto Ruiz-Cordero, Wei Chen, et al.
American Journal of Hematology
|
September 19, 2022
Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes
Daniel Rivera, Kunhwa Kim, Rashmi Kanagal-Shamanna, et al.
JCO Precision Oncology
|
May 17, 2023
Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in <i>ABL</i> Class Rearrangements
Jayastu Senapati, Elias Jabbour, Marina Konopleva, et al.
Blood Advances
|
December 19, 2023
Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax
Alex Bataller, Alexandre Bazinet, Courtney D DiNardo, et al.
American Journal of Hematology
|
February 16, 2024
Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups
Alex Bataller, Courtney D DiNardo, Alexandre Bazinet, et al.
Frontiers in Antibiotics
|
June 6, 2025
Inclusion of patient-centered, non-microbiological endpoints and biomarkers in tuberculosis drug trials
Andrew R DiNardo, Wilbert Sabiiti, Stephen H Gillespie, et al.
American Journal of Hematology
|
December 24, 2024
Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High-Risk Subtype That Warrants an Independent Prognostic Designation
Jayastu Senapati, Hagop M Kantarjian, Fadi G Haddad, et al.
The Journal of Sexual Medicine
|
November 1, 2019
Clinical and Genetic Predictors of Priapism in Sickle Cell Disease: Results from the Recipient Epidemiology and Donor Evaluation Study III Brazil Cohort Study
Mina Cintho Ozahata, Grier P Page, Yuelong Guo, et al.
The Lancet. Oncology
|
October 21, 2021
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial
Courtney D DiNardo, Andre C Schuh, Eytan M Stein, et al.
Page
of 149